PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
18413364-7	2008	In this study, we demonstrate the dark side of Nrf2: stable overexpression of Nrf2 resulted in enhanced resistance of cancer cells to chemotherapeutic agents including cisplatin, doxorubicin and etoposide.	Etoposide	195-204	NFE2 like bZIP transcription factor 2	Homo sapiens	47-51	
18413364-7	2008	In this study, we demonstrate the dark side of Nrf2: stable overexpression of Nrf2 resulted in enhanced resistance of cancer cells to chemotherapeutic agents including cisplatin, doxorubicin and etoposide.	Etoposide	195-204	NFE2 like bZIP transcription factor 2	Homo sapiens	78-82	
33148531-2	2021	The aim of this present study was to investigate the Nrf2 inhibitory effect of Trigonelline, its mechanism of action and its possible use in combinatorial treatment with anti- lung cancer drugs, Cisplatin and Etoposide.	Etoposide	209-218	NFE2 like bZIP transcription factor 2	Homo sapiens	53-57	
33148531-7	2021	Nrf2 knockdown experiment in NSCLC cells obliterated the effect of Trigonelline- Cisplatin and Trigonelline-Etoposide combination, indicating the role of Nrf2 inhibition in augmenting drug sensitivity.	Etoposide	108-117	NFE2 like bZIP transcription factor 2	Homo sapiens	0-4	
27982581-8	2017	Interestingly, Nrf2 knockdown caused an inhibition of the DNA damage response at high concentrations of etoposide, while Keap1 knockdown caused an enhancement of the DNA damage response already at low concentrations of etoposide.	Etoposide	104-113	NFE2 like bZIP transcription factor 2	Homo sapiens	15-19	
27661668-11	2016	Depending on Nrf2-induced proteasome activity, IMC-cocultured NCM460 or Colo320 cancer cells were less sensitive to apoptosis (TRAIL-/etoposide induced).	Etoposide	134-143	NFE2 like bZIP transcription factor 2	Homo sapiens	13-17	
22275372-8	2012	Moreover, dysfunctional/mutant inhibitor of Nrf2 (INrf2) in human lung cancer cells failed to degrade Nrf2, resulting in an increased Bcl-2 level and decreased etoposide- and UV/gamma radiation-mediated DNA fragmentation.	Etoposide	160-169	NFE2 like bZIP transcription factor 2	Homo sapiens	44-48	
26708503-2	2016	Consistent with previous findings that NRF2-ARE contributes to chemotherapeutic resistance of cancer cells, we found that stable knockdown of NRF2 by lentiviral shRNA in human acute monocytic leukemia (AML) THP-1 cells enhanced the cytotoxicity of several chemotherapeutic agents, including arsenic trioxide (As2O3), etoposide and doxorubicin.	Etoposide	317-326	NFE2 like bZIP transcription factor 2	Homo sapiens	142-146	
22275372-8	2012	Moreover, dysfunctional/mutant inhibitor of Nrf2 (INrf2) in human lung cancer cells failed to degrade Nrf2, resulting in an increased Bcl-2 level and decreased etoposide- and UV/gamma radiation-mediated DNA fragmentation.	Etoposide	160-169	NFE2 like bZIP transcription factor 2	Homo sapiens	51-55	
22275372-10	2012	Furthermore, the specific knockdown of Bcl-2 in Nrf2-activated tumor cells led to increased etoposide-induced apoptosis and decreased cell survival and growth/proliferation.	Etoposide	92-101	NFE2 like bZIP transcription factor 2	Homo sapiens	48-52	
22142473-6	2012	Moreover, targeting the Nrf2/HO-1 axis sensitized GI-ME-N cells to etoposide more than GSH depletion.	Etoposide	67-76	NFE2 like bZIP transcription factor 2	Homo sapiens	24-28	
19920073-13	2009	The antioxidant activation of Nrf2 reduced etoposide-mediated DNA fragmentation and promoted cell survival in PKC-delta(+/+) but not in PKC-delta(-/-) cells.	Etoposide	43-52	NFE2 like bZIP transcription factor 2	Homo sapiens	30-34